Vertex Pharmaceuticals Incorpor Price Today
Vertex Pharmaceuticals Incorpor
VRTX
Healthcare
$87.69B
💰
Market Cap
27.1
💸
Price to Earnings
$12.6
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
16 |
Strong Buy |
10 |
Hold |
11 |
Sell |
0 |
Strong Sell |
0 |
VRTX Price Forecast Target
340.5 👉 456.0 +34%
VRTX EPS Forecast
12.6 👉 16.1 +28%
Financials
Profit Margin
35 %
Revenue Growth
13.5 %
Dividend
$ 0
Held Percent
0.2% - Insiders
96.5% - Institutions
3.3% - Public
Major Fund Holders
-
💰 Blackrock Inc. $7.5B
-
💰 Vanguard Group Inc $6.9B
-
💰 FMR, LLC $5.1B
-
💰 Capital World Investors $5.1B
-
💰 State Street Corporation $3.8B
Stock Ideas
Howard Marks Portfolio
Meet Howard Marks, the co-founder and lead of Oaktree Capital Management, a Los Angeles-based investment firm that manages roughly $78 billion in investment capital. Marks has an impressive background in distressed debt, high yield bonds, and conver…
Warren Buffet Portfolio
Invest like the oracle himself! View the stocks that Warren Buffett holds in the Berkshire Hathaway portfolio.
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Paul Tudor Jones Portfolio
Paul Tudor Jones is a pioneer in macro trading and founder of Tudor Investment Corporation, one of the earliest pioneering hedge funds. With over 40 years of experience investing across global markets, Jones strategically allocates capital based on …📮FAQ
Some Frequently Asked Questions.
The Vertex Pharmaceuticals Incorpor industry is Biotechnology
The Vertex Pharmaceuticals Incorpor sector is Healthcare
The Vertex Pharmaceuticals Incorpor forecasted predicted Price to Earnings PE ratio is 21.1
The Vertex Pharmaceuticals Incorpor Price to Earnings PE ratio is 27.1
The Market Capitalization of Vertex Pharmaceuticals Incorpor is $87.69B
There are total of 257385054 float shares with 96.5% held by Institutions and 0.2% held by insiders
The MVertex Pharmaceuticals Incorpor forecasted Earnings per Share EPS is $16.1
The Vertex Pharmaceuticals Incorpor Earnings per Share EPS is 12.6
The Vertex Pharmaceuticals Incorpor company has $5323100000 gross profits with 35 profit margins
The Vertex Pharmaceuticals Incorpor Earnings Growth is 0.125% with 0.13% quarterly earnings growth
The Vertex Pharmaceuticals Incorpor Revenue is $9505000448 with 0.135 revenue growth
The price target for Vertex Pharmaceuticals Incorpor stock is $456.0 for the high target and $312.0 for the low target
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, with the following breakdown:
- Buy: 16
- Strong Buy: 10
- Hold: 11
- Sell: 0
- Strong Sell: 0
The Beta of Vertex Pharmaceuticals Incorpor is 0.5
The dividend of Vertex Pharmaceuticals Incorpor is $0
The dividend yield of Vertex Pharmaceuticals Incorpor is 0%
The biggest institutional and mutual fund holders of Vertex Pharmaceuticals Incorpor stock are
- Blackrock Inc.
- Vanguard Group Inc
- FMR, LLC
- Capital World Investors
The Vertex Pharmaceuticals Incorpor ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0